Table 3.
Effect of glycerol supplementation and L. reuteri PTA5_F13 on the metabolic activity of chicken cecal microbiota during in vitro F3
| Reactors | Mean metabolite concentration (mM) ± SD | Ratios of Total SCFAs (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Acetate | Butyrate | Propionate | Succinate | Valerate | 1,3 – PDO | Total BCFAs | Total metabolites | Acetate | Butyrate | Propionate | |
| Control | |||||||||||
| Pre-treatment | 83.9 ± 1.9 | 48.7 ± 0.5 | 11.7 ± 0.6 | 2.4 ± 1.5 | 9.7 ± 0.5 | 0.0 ± 0.0 | 15.0 ± 0.3 | 171.1 ± 4.0 | 58.1 ± 0.2 | 33.7 ± 0.6 | 8.1 ± 0.2 |
| Treatment | 76.5 ± 1.1 | 46.4 ± 0.6 | 10.7 ± 0.3 | 1.1 ± 0.1 | 9.0 ± 0.1 | 0.0 ± 0.0 | 16.6 ± 0.2 | 160.7 ± 1.6 | 57.2 ± 0.1 | 34.7 ± 0.3 | 8.0 ± 0.2 |
| Treatment – Pre treatment | - 7.4 | - 2.2 | - 1.0 | - 1.3 | - 0.6 | + 1.6 | - 10.8 | - 0.8 | + 0.9 | 0.1 | |
| P value | 0.0045 | 0.0092 | 0.0609 | 0.1942 | 0.0769 | 0.0009 | 0.0123 | 0.0091 | 0.0611 | 0.6745 | |
| 100G | |||||||||||
| Pre-treatment | 95.3 ± 3.0 | 44.9 ± 1.4 | 10.3 ± 1.4 | 0.7 ± 0.1 | 9.4 ± 0.2 | 0.0 ± 0.0 | 14.9 ± 0.4 | 175.8 ± 6.1 | 63.3 ± 0.5 | 29.8 ± 0.2 | 6.8 ± 0.7 |
| Treatment | 63.2 ± 1.0 | 83.1 ± 4.1 | 5.9 ± 0.8 | 2.1 ± 1.8 | 8.1 ± 0.8 | 22.3 ± 7.4 | 16.1 ± 0.6 | 178.6 ± 1.8 | 41.5 ± 1.0 | 54.5 ± 1.5 | 3.9 ± 0.5 |
| Treatment – Pre treatment | - 32.0 | + 38.0 | - 4.3 | + 1.3 | - 1.3 | + 22.3 | + 1.0 | + 2.8 | - 21.8 | + 24.7 | - 2.9 |
| P value | 0.00006 | 0.0001 | 0.0107 | 0.1114 | 0.0511 | 0.0063 | 0.0638 | 0.4868 | 0.000005 | 0.00001 | 0.0055 |
| Lbr | |||||||||||
| Pre-treatment | 98.5 ± 2.6 | 43.7 ± 1.9 | 13.8 ± 0.5 | 1.0 ± 0.1 | 9.6 ± 0.5 | 0.0 ± 0.0 | 17.9 ± 0.5 | 184.6 ± 5.9 | 63.1 ± 0.3 | 28.0 ± 0.3 | 8.8 ± 0.1 |
| Treatment | 101.3 ± 0.9 | 36.3 ± 2.2 | 15.4 ± 1.7 | 1.0 ± 0.1 | 8.3 ± 0.3 | 0.0 ± 0.0 | 17.0 ± 0.7 | 179.8 ± 2.3 | 66.1 ± 0.2 | 23.7 ± 1.3 | 10.0 ± 1.2 |
| Treatment – Pre treatment | + 2.8 | - 7.3 | + 1.6 | - | - 1.2 | - 0.8 | - 4.8 | + 3.0 | + 4.2 | + 1.2 | |
| P value | 0.1443 | 0.0124 | 0.1853 | 0.5772 | 0.0220 | 0.1619 | 0.2624 | 0.0002 | 0.0050 | 0.1422 | |
| Lbr-100G | |||||||||||
| Pre-treatment | 94.3 ± 3.7 | 46.3 ± 1.0 | 10.5 ± 2.4 | 3.3 ± 1.8 | 9.4 ± 0.8 | 0.0 ± 0.0 | 13.7 ± 2.5 | 177.7 ± 6.1 | 62.4 ± 1.9 | 30.6 ± 1.2 | 6.9 ± 1.5 |
| Treatment | 69.6 ± 4.8 | 86.7 ± 5.2 | 5.4 ± 0.8 | 5.5 ± 1.2 | 6.4 ± 1.1 | 61.4 ± 10.7 | 14.6 ± 3.3 | 187.9 ± 5.4 | 43.0 ± 3.0 | 53.6 ± 3.2 | 3.3 ± 0.4 |
| Treatment – Pre treatment | - 24.0 | + 40.4 | - 5.1 | + 2.3 | - 3.1 | + 61.4 | + 0.5 | + 10.1 | - 19.3 | + 22.9 | - 3.6 |
| P value | 0.0021 | 0.0001 | 0.0256 | 0.1529 | 0.0170 | 0.0047 | 0.8546 | 0.0986 | 0.0007 | 0.00032 | 0.0182 |
Data are means ± SD for the last 3 days of each treatment period. Delta corresponds the difference between treatment and pre-treatment. P value is calculated for the pairwise comparison of the last 3 days of treatment and pre-treatment periods within a reactor by unpaired t-test. CR, Control reactor; 100G, 100 mM glycerol; Lbr, L. reuteri PTA5_F13; Lbr-100G, L. reuteri PTA5_F13 and 100 mM glycerol